kabutan

RIBOMIC Inc.(4591) Summary

4591
TSE Growth
RIBOMIC Inc.
84
JPY
-2
(-2.33%)
Jan 29, 3:30 pm JST
0.54
USD
Jan 29, 1:30 am EST
Result
PTS
outside of trading hours
84.9
Jan 29, 8:57 pm JST
Summary Chart Historical News Financial Result
PER
PBR
1.41
Yield
ー%
Margin Trading Ratio
Stock Price
Jan 29, 2026
Opening Jan 29, 9:00 am
86 JPY 0.56 USD
Previous Close Jan 28
86 JPY 0.56 USD
High Jan 29, 9:00 am
86 JPY 0.56 USD
Low Jan 29, 9:40 am
84 JPY 0.54 USD
Volume
424,700
Trading Value
0.04B JPY 0.24M USD
VWAP
84.8 JPY 0.55 USD
Minimum Trading Value
8,400 JPY 54 USD
Market Cap
4.56B JPY 0.03B USD
Number of Trades
94
Liquidity & Number of Trades
As of Jan 29, 2026
Liquidity
Slightly High
1-Year Average
442
1-Year High Jun 19, 2025
7,834
Margin Trading
Date Short Interest Long Margin Positions Ratio
Jan 23, 2026 0 8,155,000
Jan 16, 2026 0 7,910,100
Jan 9, 2026 1,000 7,915,900 7915.90
Dec 26, 2025 0 7,755,300
Dec 19, 2025 0 7,714,500
Company Profile
RIBOMIC Inc. is a drug discovery venture originating from the University of Tokyo. The company develops molecular targeted drugs utilizing RNA and collaborates with major pharmaceutical companies.
Sector
Pharmaceuticals
RIBOMIC Inc. is a biotech venture company specializing in the development of aptamer drugs (molecular targeted therapies) originating from the University of Tokyo. The company conducts innovative research and development of aptamer drugs using its proprietary "RiboART System" technology platform. Its main pipeline includes the clinical development of umedaptanib pegol for age-related macular degeneration and achondroplasia. RIBOMIC is also developing multiple aptamer drug candidates for conditions such as pulmonary arterial hypertension and proliferative vitreoretinopathy. In the ophthalmology field, the company has a joint research agreement with the University of Tokyo. Additionally, through collaborations with pharmaceutical companies and in-house drug discovery efforts, RIBOMIC aims to create treatments for diseases with high unmet medical needs.